Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

Although neonatal RDS is still the main indication of surfactant therapy, other pathological processes received considerable attention and major research has been dedicated to explore the role of surfactant in their management, Meconium aspiration syndrome (MAS) and congenital pneumonia are two worthy examples.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949959/

According to Verified Market Research, The Global Pneumonia Therapeutics Market was valued at USD 2.2 Billion in 2020 and is projected to reach USD 7.2 Billion

https://www.verifiedmarketresearch.com/product/pneumonia-therapeutics-market/

Porcine versus bovine surfactant therapy for RDS in preterm neonates: pragmatic meta-analysis and review of physiopathological plausibility of the effects on extra-pulmonary outcomes

https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-019-1267-8

HOW ABOUT AN INFUSION OF SAFE AND EFFECTIVE ZYESAMI(TM) FOR ALL SOON-TO-BE MOMS???

Which treatment is prescribed for the newborn with meconium aspiration syndrome?

Suctioning the baby's upper airways, including the nose, mouth and throat. Giving the baby supplemental oxygen by hood or mechanical ventilator. Tapping on the baby's chest to loosen secretions, a technique known as chest physiotherapy. Antibiotics to treat infection.

http://emedicine.medscape.com/article/974110-medication